ID   SK-MEL-37
AC   CVCL_3878
SY   SK-Mel-37; SK-MEL37; SK-Mel 37; SK MEL 37; Sk Mel37; SKMEL-37; SK-37; SK37-MEL; BD-Mel
DR   BTO; BTO_0002967
DR   EFO; EFO_0022424
DR   cancercelllines; CVCL_3878
DR   Cosmic; 706102
DR   Cosmic; 721826
DR   Cosmic; 851046
DR   Cosmic; 888842
DR   Cosmic; 933137
DR   Cosmic; 1303056
DR   Cosmic; 1669151
DR   Millipore; SCC262
DR   Wikidata; Q54954130
RX   DOI=10.1007/978-1-4615-7228-2_39;
RX   PubMed=313568;
RX   PubMed=978138;
RX   PubMed=1067619;
RX   PubMed=1778766;
RX   PubMed=2784858;
RX   PubMed=2983346;
RX   PubMed=3081645;
RX   PubMed=3518877;
RX   PubMed=6197381;
RX   PubMed=6582512;
RX   PubMed=6864164;
RX   PubMed=6933476;
RX   PubMed=7017212;
RX   PubMed=7175440;
RX   PubMed=9598804;
RX   PubMed=9692547;
RX   PubMed=10766161;
RX   PubMed=15009714;
RX   PubMed=21725359;
RX   PubMed=24576830;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714; PubMed=21725359; PubMed=24576830).
CC   Sequence variation: Mutation; HGNC; HGNC:1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=9692547).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): Millipore=SCC262
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 12,14
ST   D18S51: 12,16
ST   D21S11: 28,30
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 9
ST   D8S1179: 12,15
ST   FGA: 19,23
ST   Penta D: 9,13
ST   Penta E: 7,12
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C4633; Amelanotic cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 32
//
RX   DOI=10.1007/978-1-4615-7228-2_39;
RA   Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Malignant melanoma. Current status of the search for melanoma-specific
RT   antigens.";
RL   (In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston; USA (1981).
//
RX   PubMed=313568; DOI=10.1073/pnas.76.6.2898; PMCID=PMC383717;
RA   Carey T.E., Lloyd K.O., Takahashi T., Travassos L.R., Old L.J.;
RT   "AU cell-surface antigen of human malignant melanoma: solubilization
RT   and partial characterization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:2898-2902(1979).
//
RX   PubMed=978138; DOI=10.1084/jem.144.4.873; PMCID=PMC2190439;
RA   Shiku H., Takahashi T., Oettgen H.F., Old L.J.;
RT   "Cell surface antigens of human malignant melanoma. II. Serological
RT   typing with immune adherence assays and definition of two new surface
RT   antigens.";
RL   J. Exp. Med. 144:873-881(1976).
//
RX   PubMed=1067619; DOI=10.1073/pnas.73.9.3278; PMCID=PMC431008;
RA   Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F.,
RA   Old L.J.;
RT   "Cell surface antigens of human malignant melanoma: mixed
RT   hemadsorption assays for humoral immunity to cultured autologous
RT   melanoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
//
RX   PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x; PMCID=PMC5918361;
RA   Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M.,
RA   Ohnishi Y., Xiao H.-Y., Nagai Y., Takagi H.;
RT   "Aberrant elevation of tyrosine-specific phosphorylation in human
RT   gastric cancer cells.";
RL   Jpn. J. Cancer Res. 82:1428-1435(1991).
//
RX   PubMed=2784858; DOI=10.1073/pnas.86.8.2804; PMCID=PMC287007;
RA   Knuth A., Wolfel T., Klehmann-Hieb E., Boon T.,
RA   Meyer zum Buschenfelde K.-H.;
RT   "Cytolytic T-cell clones against an autologous human melanoma:
RT   specificity study and definition of three antigens by
RT   immunoselection.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:2804-2808(1989).
//
RX   PubMed=2983346; DOI=10.1073/pnas.82.5.1470; PMCID=PMC397284;
RA   Dracopoli N.C., Houghton A.N., Old L.J.;
RT   "Loss of polymorphic restriction fragments in malignant melanoma:
RT   implications for tumor heterogeneity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985).
//
RX   PubMed=3081645; DOI=10.4049/jimmunol.136.7.2534;
RA   Panneerselvam M., Welt S., Old L.J., Vogel C.-W.;
RT   "A molecular mechanism of complement resistance of human melanoma
RT   cells.";
RL   J. Immunol. 136:2534-2541(1986).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6197381; DOI=10.1002/ijc.2910320610;
RA   Mattes M.J., Thomson T.M., Old L.J., Lloyd K.O.;
RT   "A pigmentation-associated, differentiation antigen of human melanoma
RT   defined by a precipitating antibody in human serum.";
RL   Int. J. Cancer 32:717-721(1983).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6864164; DOI=10.1084/jem.158.1.53; PMCID=PMC2187084;
RA   Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F.,
RA   Old L.J.;
RT   "Detection of cell surface and intracellular antigens by human
RT   monoclonal antibodies. Hybrid cell lines derived from lymphocytes of
RT   patients with malignant melanoma.";
RL   J. Exp. Med. 158:53-65(1983).
//
RX   PubMed=6933476; DOI=10.1073/pnas.77.7.4260; PMCID=PMC349812;
RA   Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F.,
RA   Old L.J.;
RT   "Serological survey of normal humans for natural antibody to cell
RT   surface antigens of melanoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=7175440; DOI=10.1084/jem.156.6.1755; PMCID=PMC2186870;
RA   Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.;
RT   "Surface antigens of melanocytes and melanomas. Markers of melanocyte
RT   differentiation and melanoma subsets.";
RL   J. Exp. Med. 156:1755-1766(1982).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=9692547; DOI=10.1038/sj.onc.1201881;
RA   Tsao H., Zhang X., Benoit E., Haluska F.G.;
RT   "Identification of PTEN/MMAC1 alterations in uncultured melanomas and
RT   melanoma cell lines.";
RL   Oncogene 16:3397-3402(1998).
//
RX   PubMed=10766161;
RA   Tsao H., Zhang X., Fowlkes K., Haluska F.G.;
RT   "Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous
RT   melanoma cell lines.";
RL   Cancer Res. 60:1800-1804(2000).
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x; PMCID=PMC2586668;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H.F., Liu C., Merghoub T., Hefter B.E., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R.D., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//